Guggenheim Capital LLC Acquires 27,518 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)

Guggenheim Capital LLC lifted its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 133.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 48,131 shares of the company's stock after purchasing an additional 27,518 shares during the quarter. Guggenheim Capital LLC's holdings in Denali Therapeutics were worth $981,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in DNLI. Sterling Capital Management LLC increased its stake in Denali Therapeutics by 589.9% in the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock valued at $36,000 after buying an additional 1,516 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Denali Therapeutics by 30.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock valued at $77,000 after acquiring an additional 885 shares in the last quarter. KBC Group NV increased its position in shares of Denali Therapeutics by 75.8% in the fourth quarter. KBC Group NV now owns 6,334 shares of the company's stock valued at $129,000 after acquiring an additional 2,731 shares during the last quarter. AlphaQuest LLC raised its holdings in Denali Therapeutics by 177.1% during the fourth quarter. AlphaQuest LLC now owns 6,961 shares of the company's stock worth $142,000 after acquiring an additional 4,449 shares in the last quarter. Finally, E Fund Management Co. Ltd. boosted its position in Denali Therapeutics by 32.2% during the fourth quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company's stock valued at $204,000 after purchasing an additional 2,436 shares during the last quarter. Institutional investors own 92.92% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on DNLI shares. William Blair restated an "outperform" rating on shares of Denali Therapeutics in a research note on Friday, February 28th. Cantor Fitzgerald upgraded Denali Therapeutics from a "neutral" rating to an "overweight" rating in a research note on Thursday, April 10th. Morgan Stanley assumed coverage on Denali Therapeutics in a research note on Friday, March 7th. They set an "overweight" rating and a $33.00 target price for the company. Bank of America dropped their price target on Denali Therapeutics from $30.00 to $28.00 and set a "buy" rating on the stock in a research note on Monday, March 10th. Finally, B. Riley reaffirmed a "buy" rating and set a $35.00 price objective (down from $38.00) on shares of Denali Therapeutics in a research report on Wednesday, March 5th. One equities research analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $37.57.

Denali Therapeutics Stock Performance

Shares of DNLI stock opened at $14.60 on Wednesday. Denali Therapeutics Inc. has a fifty-two week low of $10.57 and a fifty-two week high of $33.33. The stock's fifty day moving average price is $15.34 and its two-hundred day moving average price is $21.06. The company has a market cap of $2.12 billion, a PE ratio of -5.29 and a beta of 1.58.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.67) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.08. On average, equities analysts predict that Denali Therapeutics Inc. will post -2.71 EPS for the current fiscal year.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.